Prevention of autoimmune diabetes by immunogene therapy...

Details Prevention of autoimmune diabetes by immunogene therapy... Prevention of autoimmune diabetes by immunogene therapy...

2006-01-31

2006-01-31

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S199100, C424S204100, C424S232100, C424S093100, C424S093200, C424S094100

Reexamination Certificate

active

06991792

ABSTRACT:
A vaccine including recombinant vaccinia virus (ATCC VR-1354) having an inserted gene for coding glutamic acid decarboxylase is used for preventing type 1 diabetes mellitus. The glutamic acid decarboxylase expressed from the recombinant virus suppresses or tolerizes the autoreactive T cell, and induces immunological tolerance, thus effectively prevents or delays the development of type 1 diabetes mellitus.

REFERENCES:
patent: 5891435 (1999-04-01), Muir et al.
Couzin Science vol. 300 Jun. 20, 2003 pp. 1862-1865.
Moss et al. Nucleic Acids Research 1990, 18:4285-4286.
H.S. Jun, et al. “Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase.” Diabetologia. vol. 45, Apr. 4, 2002. pp. 668-675.
Receipt in the Case of the Original Deposit under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, Nov. 20, 2000.

Affiliated with

Also associated with

Rating

Prevention of autoimmune diabetes by immunogene therapy... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prevention of autoimmune diabetes by immunogene therapy..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of autoimmune diabetes by immunogene therapy... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3567656